RANKL inhibition for the management of patients with benign metabolic bone disorders

AD Anastasilakis, KA Toulis, SA Polyzos… - Expert opinion on …, 2009 - Taylor & Francis
The receptor activator of NF-κB ligand (RANKL) is a member of the TNF receptor
superfamily, essential for osteoclastogenesis. It binds to its receptor activator of NF-κB on the …
被引用次数：49 相关文章

RANKL inhibition for the management of patients with benign metabolic bone disorders.

AD Anastasilakis, KA Toulis, SA Polyzos… - Expert Opinion on …, 2009 - europepmc.org
The receptor activator of NF-kappaB ligand (RANKL) is a member of the TNF receptor
superfamily, essential for osteoclastogenesis. It binds to its receptor activator of NF-kappaB …

RANKL inhibition for the management of patients with benign metabolic bone disorders

AD Anastasilakis, KA Toulis… - Expert opinion on …, 2009 - pubmed.ncbi.nlm.nih.gov
The receptor activator of NF-kappaB ligand (RANKL) is a member of the TNF receptor
superfamily, essential for osteoclastogenesis. It binds to its receptor activator of NF-kappaB …